CL2017000662A1 - Inhibidores de la histona desmetilasa. - Google Patents

Inhibidores de la histona desmetilasa.

Info

Publication number
CL2017000662A1
CL2017000662A1 CL2017000662A CL2017000662A CL2017000662A1 CL 2017000662 A1 CL2017000662 A1 CL 2017000662A1 CL 2017000662 A CL2017000662 A CL 2017000662A CL 2017000662 A CL2017000662 A CL 2017000662A CL 2017000662 A1 CL2017000662 A1 CL 2017000662A1
Authority
CL
Chile
Prior art keywords
histone demethylase
demethylase inhibitors
inhibitors
histone
pirrolo
Prior art date
Application number
CL2017000662A
Other languages
English (en)
Inventor
Young K Chen
Michael Brennan Wallace
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of CL2017000662A1 publication Critical patent/CL2017000662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE PIRROLO[3,2-b]PIRIDINA O SALES DE ELLOS , INHIBIDORES DE HISTONA DESMETILASA; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA EL TRATAMIENTO DEL CANCER.</p>
CL2017000662A 2014-09-17 2017-03-17 Inhibidores de la histona desmetilasa. CL2017000662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051850P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
CL2017000662A1 true CL2017000662A1 (es) 2018-03-23

Family

ID=55533717

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000662A CL2017000662A1 (es) 2014-09-17 2017-03-17 Inhibidores de la histona desmetilasa.

Country Status (17)

Country Link
US (3) US9758517B2 (es)
EP (1) EP3194387B1 (es)
JP (2) JP6723663B2 (es)
KR (1) KR20170048601A (es)
CN (1) CN107001330A (es)
AU (1) AU2015318111A1 (es)
BR (1) BR112017005510A2 (es)
CA (1) CA2961580A1 (es)
CL (1) CL2017000662A1 (es)
CO (1) CO2017003445A2 (es)
EA (1) EA201790604A1 (es)
EC (1) ECSP17022542A (es)
ES (1) ES2751464T3 (es)
IL (1) IL251184A0 (es)
MX (1) MX2017003463A (es)
SG (1) SG11201702119PA (es)
WO (1) WO2016044138A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
SG11201702119PA (en) * 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
KR102615821B1 (ko) * 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 불소-치환된 인다졸 화합물 및 이의 용도
CN109709333B (zh) * 2018-08-01 2021-09-24 东南大学 H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5784274B2 (ja) 2006-12-04 2015-09-24 ノバルティス アーゲー Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ
JP2010526048A (ja) 2007-05-04 2010-07-29 アストラゼネカ アクチボラグ アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
UA102336C2 (uk) * 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
US9988377B2 (en) 2011-08-24 2018-06-05 The Trustees Of Columbia University In The City Of New York Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders
ES2654143T3 (es) * 2012-10-02 2018-02-12 Gilead Sciences, Inc. Inhibidores de desmetilasas de histonas
SI2934145T1 (en) 2012-12-19 2018-03-30 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6320506B2 (ja) * 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
SG11201702119PA (en) * 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors

Also Published As

Publication number Publication date
EP3194387A1 (en) 2017-07-26
US10231957B2 (en) 2019-03-19
ECSP17022542A (es) 2017-05-31
US20170326116A1 (en) 2017-11-16
EP3194387B1 (en) 2019-07-31
CA2961580A1 (en) 2016-03-24
IL251184A0 (en) 2017-05-29
US9758517B2 (en) 2017-09-12
MX2017003463A (es) 2017-07-13
AU2015318111A1 (en) 2017-04-13
WO2016044138A1 (en) 2016-03-24
US20160108032A1 (en) 2016-04-21
CO2017003445A2 (es) 2017-07-11
BR112017005510A2 (pt) 2018-08-14
JP6967632B2 (ja) 2021-11-17
EA201790604A1 (ru) 2017-09-29
US20180271843A1 (en) 2018-09-27
US10016401B2 (en) 2018-07-10
JP6723663B2 (ja) 2020-07-15
CN107001330A (zh) 2017-08-01
ES2751464T3 (es) 2020-03-31
SG11201702119PA (en) 2017-04-27
EP3194387A4 (en) 2018-03-07
JP2017529347A (ja) 2017-10-05
KR20170048601A (ko) 2017-05-08
JP2020169183A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016002548A1 (es) Derivados de tubulisina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.